IRIS
Di Lorenzo, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.810
NA - Nord America 3.171
SA - Sud America 1.458
EU - Europa 540
AF - Africa 226
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.888
SG - Singapore 1.386
BR - Brasile 1.043
CN - Cina 687
HK - Hong Kong 549
BD - Bangladesh 317
IT - Italia 262
VN - Vietnam 237
MX - Messico 153
IN - India 129
AR - Argentina 123
IQ - Iraq 76
EC - Ecuador 70
CA - Canada 69
TR - Turchia 66
CO - Colombia 63
ID - Indonesia 62
VE - Venezuela 55
SA - Arabia Saudita 47
ZA - Sudafrica 47
GB - Regno Unito 43
PK - Pakistan 40
PH - Filippine 38
RU - Federazione Russa 38
MA - Marocco 37
PY - Paraguay 31
TN - Tunisia 30
DE - Germania 29
CL - Cile 28
UA - Ucraina 27
UZ - Uzbekistan 27
MY - Malesia 26
FR - Francia 25
NL - Olanda 24
EG - Egitto 23
KE - Kenya 21
ES - Italia 19
AE - Emirati Arabi Uniti 16
BO - Bolivia 16
ET - Etiopia 15
JO - Giordania 14
LB - Libano 13
PE - Perù 13
UY - Uruguay 13
DZ - Algeria 12
JM - Giamaica 11
OM - Oman 11
CR - Costa Rica 9
NP - Nepal 9
AL - Albania 8
AZ - Azerbaigian 8
KG - Kirghizistan 8
CH - Svizzera 7
LY - Libia 7
RS - Serbia 7
TH - Thailandia 7
KZ - Kazakistan 6
PS - Palestinian Territory 6
PT - Portogallo 6
RO - Romania 6
BY - Bielorussia 5
DO - Repubblica Dominicana 5
GE - Georgia 5
PA - Panama 5
SN - Senegal 5
TT - Trinidad e Tobago 5
AO - Angola 4
AU - Australia 4
BB - Barbados 4
BH - Bahrain 4
CM - Camerun 4
HN - Honduras 4
HU - Ungheria 4
NG - Nigeria 4
NI - Nicaragua 4
BA - Bosnia-Erzegovina 3
BS - Bahamas 3
CZ - Repubblica Ceca 3
GR - Grecia 3
GT - Guatemala 3
IL - Israele 3
PL - Polonia 3
AT - Austria 2
BE - Belgio 2
CI - Costa d'Avorio 2
FI - Finlandia 2
HT - Haiti 2
KR - Corea 2
LI - Liechtenstein 2
ML - Mali 2
SC - Seychelles 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BG - Bulgaria 1
BZ - Belize 1
CD - Congo 1
CG - Congo 1
CV - Capo Verde 1
Totale 9.179
Salva come PNG Salva come JPEG
Città #
San Jose 1.938
Singapore 812
Hong Kong 527
Ashburn 356
Beijing 333
Mexico City 122
Ho Chi Minh City 97
São Paulo 73
New York 60
Hanoi 51
Santa Clara 41
Rome 39
Naples 36
Rio de Janeiro 31
Baghdad 30
Tashkent 25
Quito 23
Belo Horizonte 22
Brasília 22
Lahore 22
Milan 22
Caracas 20
Haiphong 18
Jeddah 18
Los Angeles 18
Nairobi 17
Istanbul 16
Johannesburg 16
Santiago 16
Buffalo 15
Campinas 15
Curitiba 15
Guayaquil 15
Medellín 15
Toronto 15
Chicago 14
Salvador 14
Addis Ababa 13
Amman 13
Dhaka 13
Asunción 12
Buenos Aires 12
Kuala Lumpur 12
Montevideo 11
Riyadh 11
Bogotá 10
Cape Town 10
Casablanca 10
Dammam 10
Jakarta 10
London 10
Porto Alegre 10
Santo André 10
Cairo 9
Erbil 9
Goiânia 9
Muscat 9
Palermo 9
San José 9
Sorocaba 9
Tunis 9
Hyderabad 8
La Paz 8
New Delhi 8
Ribeirão Preto 8
Uberlândia 8
Atlanta 7
Baku 7
Boardman 7
Dallas 7
Delhi 7
Fortaleza 7
João Pessoa 7
Lima 7
Manaus 7
Philadelphia 7
Bologna 6
Cali 6
Contagem 6
Córdoba 6
Dubai 6
Guarulhos 6
Joinville 6
Karbala 6
Kingston 6
Maringá 6
Mauá 6
Mumbai 6
Rabat 6
São Bernardo do Campo 6
Tirana 6
Adana 5
Agadir 5
Barquisimeto 5
Belford Roxo 5
Belém 5
Biên Hòa 5
Charlotte 5
Cleveland 5
Cuenca 5
Totale 5.433
Salva come PNG Salva come JPEG
Nome #
The use of tamsulosin in the medical treatment of ureteral calculi: Where do we stand? 78
Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 68
Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis 63
Effect of baseline characteristics on cabazitaxel treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC): a post hoc analysis of the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry 63
Statin use and survival in patients with metastatic castrationresistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study 62
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 60
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml 59
Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study 59
Synergistic Combination of Quercetin and Mafosfamide in the Treatment of Bladder Cancer Cells 55
A case of renal melanoma metastasis: Description of clinico-pathological features 53
Management of AIDS-related Kaposi's sarcoma 51
Multicenter clinical trial of the efficacy and safety of rokitamycin in ENT infections 50
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: A phase I clinical trial 49
Imatinib mesylate in thymic epithelial malignancies 49
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis 49
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: A retrospective Italian survey 48
Evaluation of Directed Graph-Mapping in Complex Atrial Tachycardias 45
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers 42
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients 41
Development and Validation of the PREVESMED Questionnaire: A Comprehensive Tool for Assessing Adherence to a Mediterranean Lifestyle 40
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma 39
Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3 39
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 39
Clinical characteristics of metastatic prostate cancer patients infected with COVID-19 in South Italy 39
Immunotherapy for the treatment of prostate cancer 37
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis 37
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor 37
Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review 37
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs) 37
Predictors of Residual T1 High Grade on Re- Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer 36
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor 36
The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study 36
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis 36
Update on classic Kaposi sarcoma therapy: New look at an old disease 36
Contralateral prophylactic mastectomy in male breast cancer: Where do we stand 36
A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario 36
Gemcitabine Versus Bacille Calmette-Guerin After Initial Bacille Calmette-Guerin Failure in Non-Muscle-Invasive Bladder Cancer A Multicenter Prospective Randomized Trial 35
Impact of Dietary Supplements on Clinical Outcomes and 2 Quality of Life in Patients with Breast Cancer: A Systematic Review 35
Medical expulsive treatment of distal-ureteral stones using tamsulosin: A single-center experience 35
Validation of Psychometric Tools for Assessing Fatigue, Mood, and Sleep Quality: Application in the PREVES-STOP Study. 34
The evolving systemic treatment landscape for patients with advanced prostate cancer 34
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry 34
It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature 33
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 33
Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma. 33
Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 33
A Prognostic Model for Patients With Metastatic Renal Cell Cancer: What's New? 33
Focus on localized laryngeal amyloidosis: Management of five cases 33
Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy 33
Words of Wisdom. Re: Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy 33
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis 32
The Impact of Flavonoid Supplementation on Serum Oxidative Stress Levels Measured via D-ROMs Test in the General Population: The PREVES-FLAVON Retrospective Observational Study 32
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: A phase II study 32
Optimal management of a patient with recurrent nasopharyngeal carcinoma 32
Outcomes associated with first-line PD-1 and PD-L1 inhibitors vs. sunitinib in patients with renal cell cancer with sarcomatoid features: a systematic review and meta-analysis 32
Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer 32
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced 32
A comprehensive outlook on intracerebral therapy of malignant gliomas. 32
Instant messaging in cancer care 31
Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme 31
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis 31
Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible? 31
Chirurgia conservativa e qualità di vita in pazienti con carcinoma renale localizzato. 31
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors 31
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 31
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples 31
Vesicourethral anastomosis during radical retropubic prostatectomy: Does the number of sutures matter? 30
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: A multicenter study 30
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection 30
The use of interferon in melanoma patients: a systematic review 30
Numerical study of laminar confined impinging slot jets with nanofluids 30
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings 30
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 30
Toxicities of Targeted Therapy and Their Management in Kidney Cancer 30
Expression of HECA-452 in parapsoriasis and mycosis fungoides 30
Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era 30
Computed-Tomography-Structured Reporting in Middle Ear Opacification: Surgical Results and Clinical Considerations From a Large Retrospective Analysis 30
Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study 30
Complete response and fatigue improvement with the combined use of cyclophosphamide and quercetin in a patient with metastatic bladder cancer a case report 30
Predicting early and delayed bleedings in children who undergo adeno-tonsillectomy surgery. Is it really possible? 30
Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? 30
KIDNEY CANCER Overall survival is an unsuitable primary end point 30
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer 30
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer - A multi-institutional, long-term experience 30
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer 29
Testicular cancer from diagnosis to epigenetic factors 29
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 29
Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O). A real-world study on behalf of Meet-URO group (MeetUro-7b) 29
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study 29
New perspectives in the therapy of castration resistant prostate cancer 29
Thermal and fluid dynamic behaviors of confined laminar impinging slot jets with nanofluids 29
A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review 29
INCREASED EXPRESSION OF THE AUTOCRINE MOTILITY FACTOR IS ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH CLEAR CELL – RENAL CELL CARCINOMA 29
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 29
Prospective evaluation of entrainment mapping as an adjunct to new-generation high-density activation mapping systems of left atrial tachycardias 29
Kaempferol, myricetin and fisetin in prostate and bladder cancer: a systematic review of literature 29
Activity of platinum-based chemotherapy in advanced prostate cancer patients with and without DNA repair gene aberrations: An International Collaborative Analysis 29
Bio-inspired method for advanced industrial sludge treatment with closed cycle drying process 29
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study 28
Intralabyrinthine Schwannoma of the Intravestibular Subtype: A Difficult Diagnosis 28
Totale 3.654
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20252.165 0 0 0 28 338 19 114 372 101 60 553 580
2025/20267.416 266 27 355 434 922 444 687 408 2.064 1.118 603 88
Totale 9.581